Danaher Croissance future

Future contrôle des critères 1/6

Danaher devrait augmenter ses bénéfices et son chiffre d'affaires de 14% et de 6.4% par an respectivement. Le BPA devrait croître de de 14.3% par an. Le rendement des capitaux propres devrait être 11.1% dans 3 ans.

Informations clés

14.0%

Taux de croissance des bénéfices

14.3%

Taux de croissance du BPA

Life Sciences croissance des bénéfices	18.4%
Taux de croissance des recettes	6.4%
Rendement futur des capitaux propres	11.1%
Couverture par les analystes	Good
Dernière mise à jour	20 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Mar Vista - Danaher: Headwinds Are Primarily Cyclical, Growth To Regain Momentum

Jun 20

Is Danaher Corporation (NYSE:DHR) Worth US$263 Based On Its Intrinsic Value?

Jun 05

Is Danaher (NYSE:DHR) A Risky Investment?

May 21

It's Unlikely That Danaher Corporation's (NYSE:DHR) CEO Will See A Huge Pay Rise This Year

May 01

Value Vs. Growth? Danaher Says Why Not Both?

Apr 25

Danaher: All In On Life Sciences, And Market Update

Mar 27

Is Now An Opportune Moment To Examine Danaher Corporation (NYSE:DHR)?

Mar 11

Danaher Corporation's (NYSE:DHR) Price Is Out Of Tune With Earnings

Feb 10

Bull Case Confirmed: Danaher Is Still One Of The Best Stocks To Buy Long-Term

Jan 30

Is Danaher (NYSE:DHR) Using Too Much Debt?

Jan 12

My Top 2024 Stock Pick: Danaher

Dec 27

Danaher: Poised For Long-Term Growth Despite Near-Term Hurdles

Nov 26

RGA Investment Advisors - Danaher: Purity In The Crown Jewel Of Bioprocessing

Nov 19

Why Danaher Is One Of My Favorite Long-Term Investments

Oct 26

Danaher: Short-Term Headwinds, But Long-Term Tailwinds

Oct 17

Should Danaher Investors Sell New Veralto Shares?

Oct 02

Danaher Corporation's (NYSE:DHR) Intrinsic Value Is Potentially 18% Below Its Share Price

Sep 30

Danaher: A Lost Year

Aug 30

Third Point - Danaher: Don't Be Surprised If Growth Rate Moves To Low Teens

Aug 02

Danaher: A Compounding Icon At A Fair Price

Jul 25

These 4 Measures Indicate That Danaher (NYSE:DHR) Is Using Debt Reasonably Well

Jul 13

Calculating The Intrinsic Value Of Danaher Corporation (NYSE:DHR)

Jun 28

Danaher: Seizing The Buying Opportunity In A Temporary Bioprocessing Slump

Jun 22

At US$238, Is It Time To Put Danaher Corporation (NYSE:DHR) On Your Watch List?

Jun 15

Danaher: A Great Chance To Buy This Long-Term Compounder

May 23

With EPS Growth And More, Danaher (NYSE:DHR) Makes An Interesting Case

Apr 26

Prévisions de croissance des bénéfices et des revenus

NYSE:DHR - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	27,320	5,587	7,001	8,228	19
12/31/2025	25,287	4,830	6,017	7,345	24
12/31/2024	23,738	4,072	5,408	6,419	23
9/27/2024	23,742	3,934	4,978	6,288	N/A
6/28/2024	23,568	4,056	5,081	6,447	N/A
3/29/2024	23,737	4,069	5,548	6,956	N/A
12/31/2023	23,890	4,200	5,781	7,164	N/A
9/29/2023	21,026	4,408	6,842	8,086	N/A
6/30/2023	23,065	5,019	7,257	8,424	N/A
3/31/2023	24,904	5,757	7,364	8,498	N/A
12/31/2022	26,643	6,222	7,401	8,519	N/A
9/30/2022	31,250	6,640	7,068	8,311	N/A
7/1/2022	30,816	6,206	7,051	8,335	N/A
4/1/2022	30,283	6,206	7,162	8,455	N/A
12/31/2021	24,802	5,283	7,118	8,358	N/A
10/1/2021	28,065	5,636	7,056	8,246	N/A
7/2/2021	26,720	5,361	6,876	7,935	N/A
4/2/2021	24,799	4,595	6,351	7,260	N/A
12/31/2020	22,284	3,510	5,417	6,208	N/A
10/2/2020	20,392	3,083	4,444	5,099	N/A
7/3/2020	18,886	2,853	3,712	4,341	N/A
4/3/2020	18,034	2,614	3,439	4,068	N/A
12/31/2019	17,911	2,364	3,316	3,952	N/A
9/27/2019	15,562	2,093	3,479	4,078	N/A
6/28/2019	16,037	2,145	3,446	4,032	N/A
3/29/2019	16,573	2,166	3,311	3,896	N/A
12/31/2018	17,049	2,406	3,438	4,022	N/A
9/28/2018	19,615	2,761	3,004	3,619	N/A
6/29/2018	19,290	2,669	N/A	3,772	N/A
3/30/2018	18,819	2,553	N/A	3,747	N/A
12/31/2017	15,519	2,172	N/A	3,478	N/A
9/29/2017	17,828	2,360	N/A	3,292	N/A
6/30/2017	17,432	2,191	N/A	3,038	N/A
3/31/2017	17,164	2,051	N/A	3,309	N/A
12/31/2016	16,882	2,153	N/A	3,522	N/A
9/30/2016	16,621	1,927	N/A	4,104	N/A
7/1/2016	16,001	1,905	N/A	4,239	N/A
4/1/2016	13,663	1,775	N/A	4,051	N/A
12/31/2015	14,434	1,747	N/A	3,802	N/A
10/2/2015	15,335	1,875	N/A	3,810	N/A
7/3/2015	16,530	2,177	N/A	3,873	N/A
4/3/2015	19,186	2,521	N/A	3,771	N/A
12/31/2014	12,867	1,639	N/A	3,758	N/A
9/26/2014	19,197	2,683	N/A	3,597	N/A
6/27/2014	19,159	2,599	N/A	3,553	N/A
3/28/2014	19,336	2,583	N/A	3,460	N/A
12/31/2013	18,283	2,591	N/A	3,585	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de DHR ( 14% par an) est supérieure au taux d'épargne ( 2.6% ).

Bénéfices vs marché: Les bénéfices de DHR ( 14% par an) devraient croître plus lentement que le marché US ( 15.4% par an).

Croissance élevée des bénéfices: Les bénéfices de DHR devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de DHR ( 6.4% par an) devrait croître plus lentement que le marché de US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de DHR ( 6.4% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de DHR devrait être faible dans 3 ans ( 11.1 %).

Danaher Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates fall by 11%

Danaher Corporation Provides Earnings Guidance for the Fourth Quarter 2023

Consensus EPS estimates fall by 10%

Recent updates

Understanding Danaher's Cautiousness

Third quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Is There Now An Opportunity In Danaher Corporation (NYSE:DHR)?

Danaher Q3 Preview: Market Share Gains In Molecular Testing

Dividend of US$0.27 announced

Is Danaher Corporation (NYSE:DHR) Trading At A 32% Discount?

Here's Why Danaher (NYSE:DHR) Can Manage Its Debt Responsibly

Danaher: Lofty Price, Bright Future

Danaher Corporation (NYSE:DHR) acquired Genedata AG.

Danaher Corporation's (NYSE:DHR) Price In Tune With Earnings

CFO & Executive VP notifies of intention to sell stock

Insider recently sold US$3.9m worth of stock

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Danaher: Valuation Now Too High Even Compared To Own High Standards

What Is Danaher Corporation's (NYSE:DHR) Share Price Doing?

Mar Vista - Danaher: Headwinds Are Primarily Cyclical, Growth To Regain Momentum

Danaher Corporation Announces Executive Changes

Danaher Corporation Appoints Martin Stumpe as Chief Data & Artificial Intelligence Officer

Is Danaher Corporation (NYSE:DHR) Worth US$263 Based On Its Intrinsic Value?

Now 20% overvalued after recent price rise

Is Danaher (NYSE:DHR) A Risky Investment?

President notifies of intention to sell stock

Now 21% overvalued after recent price rise

CFO & Executive VP recently sold US$5.4m worth of stock

Dividend of US$0.27 announced

Danaher Announces Quarterly Dividend, Payable on July 26, 2024

It's Unlikely That Danaher Corporation's (NYSE:DHR) CEO Will See A Huge Pay Rise This Year

Senior VP recently sold US$1.0m worth of stock

Value Vs. Growth? Danaher Says Why Not Both?

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Danaher: All In On Life Sciences, And Market Update

Danaher Corporation to Report Q1, 2024 Results on Apr 23, 2024

Upcoming dividend of US$0.27 per share

Is Now An Opportune Moment To Examine Danaher Corporation (NYSE:DHR)?

Insider notifies of intention to sell stock

Dividend of US$0.27 announced

Danaher Corporation Approves Regular Quarterly Cash Dividend, Payable on April 26, 2024

Danaher Corporation, Annual General Meeting, May 07, 2024

Danaher Corporation's (NYSE:DHR) Price Is Out Of Tune With Earnings

Consensus EPS estimates fall by 11%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Bull Case Confirmed: Danaher Is Still One Of The Best Stocks To Buy Long-Term

Now 20% overvalued after recent price rise

Is Danaher (NYSE:DHR) Using Too Much Debt?

Danaher Corporation Provides Earnings Guidance for the Fourth Quarter 2023

My Top 2024 Stock Pick: Danaher

Danaher Corporation to Report Q4, 2023 Results on Jan 30, 2024

Upcoming dividend of US$0.24 per share at 0.5% yield

Danaher Corporation (NYSE:DHR) completed the acquisition of Abcam plc (NasdaqGS:ABCM).

Danaher Corporation Announces Quarterly Dividend, Payable on January 26, 2024

Danaher: Poised For Long-Term Growth Despite Near-Term Hurdles

RGA Investment Advisors - Danaher: Purity In The Crown Jewel Of Bioprocessing

Why Danaher Is One Of My Favorite Long-Term Investments

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 10%

Danaher: Short-Term Headwinds, But Long-Term Tailwinds

Now 20% undervalued after recent price drop

Upcoming dividend of US$0.27 per share at 0.5% yield

Danaher Corporation completed the Spin-Off of Veralto Corporation (NYSE:VLTO.WI).

Should Danaher Investors Sell New Veralto Shares?

Danaher Corporation's (NYSE:DHR) Intrinsic Value Is Potentially 18% Below Its Share Price

Danaher Corporation to Report Q3, 2023 Results on Oct 24, 2023

Danaher to Provide Cepheid's Tuberculosis Test to the Global Fund At Cost

Danaher Corporation Announces Quarterly Cash Dividend, Payable on October 27, 2023

Danaher: A Lost Year

Danaher Corporation (NYSE:DHR) entered into definitive agreement to acquire Abcam plc (NasdaqGS:ABCM) for $5.7 billion.

Levi & Korsinsky Notifies Danaher Corporation Investors of A Class Action Lawsuit and Upcoming Deadline

New minor risk - Insider selling

Lead Independent Director recently sold US$1.9m worth of stock

Third Point - Danaher: Don't Be Surprised If Growth Rate Moves To Low Teens

Executive Vice President notifies of intention to sell stock

Second quarter 2023 earnings: EPS misses analyst expectations